腎グルコーストランスポーターと抗糖尿病薬 [in Japanese] Renal Glucose Transporter and Anti-diabetic Agent [in Japanese]
Access this Article
Search this Article
Plasma glucose is continuously filtered through the glomerulus in the kidney and then reabsorbed via the transcellular transport systems. Glucose reabsorption in the kidney is mediated by a distinct class of transporters such as sodium-glucose cotransporters (SGLTs). Most of filtered glucose is reabsorbed by the low affinity/high capacity SGLT2 located in the proximal renal tubule. SGLT2 inhibitors, such as T-1095, enhance urinary glucose excretion, and consequently lower blood glucose level and control energy balance in a negative direction. The principle behind SGLT inhibition involves the amelioration of diabetic conditions without increasing body weight or the risk of hypoglycemia. A number of SGLT2 inhibitors are being developed and studies have suggested the therapeutic potential and safety of these drugs for the treatment of diabetes.
MEMBRANE 33(3), 102-107, 2008-05-01
THE MEMBRANE SOCIETY OF JAPAN